eligibility_summary
Eligible: adults (≥18) starting nivolumab, pembrolizumab, ipilimumab, bevacizumab, trastuzumab, durvalumab, or atezolizumab, no known heightened susceptibility to immunologic reactions, able/willing to consent. Exclude: other research meds within 4 weeks, participation in studies requiring fixed infusion times/doses, dosing that deviates from standard protocol, receiving drugs via central venous catheter (e.g., port-a-cath).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 4 prospective study evaluating safety of shortened infusion times (after two standard cycles, tapered to 15 then 10 minutes) for seven oncology monoclonal antibodies. Drugs and mechanisms (type: mAbs): Nivolumab, Pembrolizumab—anti-PD-1 IgG4, block PD-1 on T cells to restore antitumor activity. Ipilimumab—anti-CTLA-4 IgG1, blocks CTLA-4 to enhance T-cell priming and may reduce Tregs. Durvalumab, Atezolizumab—anti-PD-L1 IgG1, block PD-L1 on tumor/immune cells, preventing PD-1 signaling. Bevacizumab—anti-VEGF-A IgG1, neutralizes VEGF to inhibit angiogenesis via VEGFR-1/2 on endothelial cells. Trastuzumab—anti-HER2 (ERBB2) IgG1, binds HER2 on tumor cells to inhibit signaling and enable ADCC. Targeted cells/pathways: PD-1/PD-L1 and CTLA-4 immune checkpoints (T cells), VEGF-VEGFR angiogenic pathway (endothelium), and HER2 oncogenic signaling (tumor cells).